ULTRALIFE CORP reported the first quarter ended March 31, 2026 results: revenue $47.4 million, net income ($0.5) million, EPS ($0.03) per basic and diluted share.
“First Quarter 2026 Financial Results Revenue was $47.4 million, a decrease of $3.3 million, or 6.5%, as compared to revenue of $50.7 million for the first quarter of 2025. Battery & Energy Products sales decreased 4.7% to $44.2 million compared to $46.3 million last year. The year-over-year decrease reflects a 5.5% decline in commercial sales due to lower oil & gas and industrial sales offsetting an increase in medical battery sales, and a 2.7% decline in government/defense sales due to the shipment of a very large order for an allied country last year. Communications Systems sales decreased by 25.7% to $3.3 million compared to $4.4 million for the same period last year, primarily attributable to the timing of expected orders. Our total backlog exiting the first quarter was $115.1 million, the highest level in the Company’s history, compared to $110.2 million exiting the fourth quarter of 2025 and $95.0 million exiting the first quarter of 2025. Gross profit was $10.1 million, or 21.3%”
Earnings Releases
ULTRALIFE CORP reported the fourth quarter ended December 31, 2025 results: revenue $48.5 million, net income ($7.4) million, EPS ($0.45) per basic and diluted share.
“Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2025 as follows: Fourth Quarter: ● Sales of $48.5 million compared to $43.9 million for the 2024 fourth quarter ● Gross profit of $12.1 million, or 24.9% of revenue, compared to $10.6 million, or 24.2% of revenue, for the 2024 fourth quarter ● Operating (loss) income of ($10.6) million, which includes a ($12.2) million intangible asset impairment charge and ($1.2) million of one-time costs, compared to $1.5 million for the 2024 fourth quarter ● GAAP EPS of ($0.45), which includes ($0.57) for the intangible asset impairment charge net of the related tax benefits, compared to $0.01 for the 2024 fourth quarter”
Auditor Changes
ULTRALIFE CORP engaged Withum Smith+Brown, PC as its auditor.
“In connection with the Replacement, on August 22, 2025, the Committee approved the engagement of Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.”
Auditor Changes
ULTRALIFE CORP dismissed Freed Maxick P.C. as its auditor.
“On August 22, 2025, the Audit and Finance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of Ultralife Corporation, Inc. (the “ Company ”) approved the replacement of Freed Maxick P.C. (“ FM ”) as the Company’s independent registered public accounting firm, due to the acquisition of certain assets of FM by Withum Smith+Brown, PC (“ Withum ”), effective immediately, and informed FM of such replacement on the date thereof (the “ Replacement ”).”
M&A Transactions
ULTRALIFE CORP completed an acquisition involving Greatbatch Ltd. for $50 million (closed 2024-10-31).
“a stock purchase agreement (the “Agreement”) with Greatbatch Ltd., a New York corporation (the “Seller”), dated September 27, 2024. The Agreement established a purchase price of $50 million for the acquisition (the “Acquisition”) subject to customary working capital and net cash adjustments. The Company funded the purchase price for the Acquisition through the New”
Earnings Releases
ULTRALIFE CORP reported financial results for first quarter ended March 31, 2024.
“On April 25, 2024, Ultralife Corporation issued a press release regarding the financial results for its first quarter ended March 31, 2024.”
Earnings Releases
ULTRALIFE CORP reported full year ended December 31, 2023 results: revenue $158.6 million, EPS Adjusted EPS of $0.52.
“representing a 134.8% year-over-year increase ● Backlog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: ● Sales of $158.6 million representing a 20.3% year-over-year increase ● Operating income of $9.5 million versus $0.1 million for 2022 ● Adjusted EPS of $0.52 compared to a loss of $0.07 for 2022 ●”
Earnings Releases
ULTRALIFE CORP reported fourth quarter ended December 31, 2023 results: revenue $44.5 million, net income $2.9 million, EPS $0.17 per diluted share.
“15, 2024 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: ● Sales of $44.5 million representing a 23.4% year-over-year increase ● Highest medical sales quarter in Company’s history ● Operating income of $3.6 million versus $0.2 million for the 2022 fourth”
Earnings Releases
ULTRALIFE CORP reported third quarter ended September 30, 2023 results: revenue $39.5 million, net income $1.3 million or $0.08 per diluted share, EPS $0.08 per diluted share.
“– October 26, 2023 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights: ● Sales of $39.5 million representing an 18.8% year-over-year increase ● Operating income of $2.1 million versus a loss of $0.6 million for the 2022 third quarter ● Adjusted EPS of $0.10 compared to a”
Shareholder Votes
ULTRALIFE CORP shareholders approved Non-binding advisory vote on the frequency of future advisory votes on executive compensation. at the 2023-07-19 meeting.
“The Company’s shareholders indicated their preference, on a non-binding advisory basis, that the frequency of future advisory votes on executive compensation be “3 Years”. The number of shares that (i) voted for 1 Year, (ii) voted for 2 Years, (iii) voted for 3 Years, and (iv) abstained from the vote, are set forth in the table below. 1 Year 2 Years 3 Years Abstain 2,803,398 30,850 8,390,107 17,029”
Shareholder Votes
ULTRALIFE CORP shareholders approved Advisory resolution on executive compensation. at the 2023-07-19 meeting.
“The Company’s shareholders approved an advisory resolution on executive compensation. The number of shares that (i) voted for the resolution, (ii) voted against the resolution, (iii) abstained from the vote, and (iv) were broker non-votes, are set forth in the table below. For Against Abstain Broker Non-Votes 11,040,202 162,753 38,429 2,354,672”
Shareholder Votes
ULTRALIFE CORP shareholders approved Ratification of the selection of Freed Maxick CPAs, P.C. as independent registered public accounting firm for 2023. at the 2023-07-19 meeting.
“The Company’s stockholders ratified the selection of the Company’s independent registered public accounting firm as Freed Maxick CPAs, P.C. for 2023. The number of shares that (i) voted for the ratification of the accounting firm, (ii) voted against the ratification, and (iii) abstained from the vote are set forth in the table below. For Against Abstain 13,565,365 15,728 14,963”
Shareholder Votes
ULTRALIFE CORP shareholders approved Election of five directors to serve for a term of one year. at the 2023-07-19 meeting.
“The Company’s stockholders elected five Directors, all of whom constitute the Company’s entire Board of Directors, to serve for a term of one year and until their successors are duly elected and qualified. The number of shares that (i) voted for the election of each Director, (ii) withheld authority to vote for each Director, and (iii) were broker non-votes, are set forth in the table below. Director For Withheld Broker Non-Votes Michael E. Manna Janie Goddard 11,145,045 11,152,413 96,339 88,971 2,354,672 2,354,672 Thomas L. Saeli 10,310,510 930,874 2,354,672 Robert W. Shaw II 10,971,487 269,897 2,354,672 Bradford T. Whitmore 10,956,195 285,189 2,354,672”
Earnings Releases
ULTRALIFE CORP reported first quarter ended March 31, 2023 results: revenue $31.9 million, net income Net loss was $0.3 million or $0.02 per diluted share, EPS $0.02 per diluted share.
“Ultralife Corporation (NASDAQ: ULBI) reported breakeven operating income and adjusted EBITDA of $1.2 million on revenue of $31.9 million for the first quarter ended March 31, 2023.”
Earnings Releases
ULTRALIFE CORP reported the fourth quarter ended December 31, 2022 results: revenue $36.1 million, net income $0.2 million, EPS $0.01 per diluted share.
“Ultralife Corporation Reports Fourth Quarter Results NEWARK, N.Y. – March 2, 2023 -- Ultralife Corporation (NASDAQ: ULBI) reported operating profit of $0.2 million and adjusted EBITDA of $2.0 million on revenue of $36.1 million for the fourth quarter ended December 31, 2022.”
Janie Goddard was appointed as independent director at ULTRALIFE CORP.
“On February 21, 2023, the Board of Directors (the “Board”) of Ultralife Corporation (the “Company”) appointed Janie Goddard as an independent director of the Company effective as of February 21, 2023.”
Michael D. Popielec resigned as Chief Executive Officer at ULTRALIFE CORP.
“replacing Michael D. Popielec who is leaving the Company and resigning from his position as a member of the Board of Directors.”
Michael E. Manna was appointed as President & CEO at ULTRALIFE CORP.
“On November 22, 2022, the Board of Directors of Ultralife Corporation (the “Company”) appointed Michael E. Manna as the Company’s President & CEO and as a member of the Board of Directors, replacing Michael D. Popielec who is leaving the Company and resigning from his position as a member of the Board of Directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.